全文获取类型
收费全文 | 2538篇 |
免费 | 163篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 48篇 |
妇产科学 | 63篇 |
基础医学 | 345篇 |
口腔科学 | 58篇 |
临床医学 | 204篇 |
内科学 | 758篇 |
皮肤病学 | 65篇 |
神经病学 | 223篇 |
特种医学 | 67篇 |
外科学 | 403篇 |
综合类 | 13篇 |
预防医学 | 88篇 |
眼科学 | 45篇 |
药学 | 127篇 |
中国医学 | 6篇 |
肿瘤学 | 207篇 |
出版年
2023年 | 13篇 |
2022年 | 23篇 |
2021年 | 37篇 |
2020年 | 22篇 |
2019年 | 44篇 |
2018年 | 43篇 |
2017年 | 43篇 |
2016年 | 57篇 |
2015年 | 52篇 |
2014年 | 56篇 |
2013年 | 56篇 |
2012年 | 88篇 |
2011年 | 121篇 |
2010年 | 68篇 |
2009年 | 70篇 |
2008年 | 111篇 |
2007年 | 100篇 |
2006年 | 116篇 |
2005年 | 120篇 |
2004年 | 115篇 |
2003年 | 85篇 |
2002年 | 100篇 |
2001年 | 92篇 |
2000年 | 107篇 |
1999年 | 76篇 |
1998年 | 34篇 |
1997年 | 24篇 |
1996年 | 27篇 |
1995年 | 14篇 |
1994年 | 25篇 |
1993年 | 26篇 |
1992年 | 75篇 |
1991年 | 76篇 |
1990年 | 51篇 |
1989年 | 70篇 |
1988年 | 53篇 |
1987年 | 57篇 |
1986年 | 55篇 |
1985年 | 58篇 |
1984年 | 30篇 |
1983年 | 32篇 |
1982年 | 11篇 |
1979年 | 23篇 |
1978年 | 22篇 |
1977年 | 22篇 |
1972年 | 10篇 |
1969年 | 18篇 |
1968年 | 21篇 |
1967年 | 9篇 |
1966年 | 10篇 |
排序方式: 共有2724条查询结果,搜索用时 15 毫秒
91.
Hirotoshi Sakaguchi Nobuhiro Nishio Asahito Hama Nozomu Kawashima Xinan Wang Atsushi Narita Sayoko Doisaki Yinyan Xu Hideki Muramatsu Nao Yoshida Yoshiyuki Takahashi Kazuko Kudo Hiroshi Moritake Kazuhiro Nakamura Ryoji Kobayashi Etsuro Ito Hiromasa Yabe Shouichi Ohga Akira Ohara Seiji Kojima 《Haematologica》2014,99(8):1312-1316
Predicting the response to immunosuppressive therapy could provide useful information to help the clinician define treatment strategies for patients with aplastic anemia. In our current study, we evaluated the relationship between telomere length of lymphocytes at diagnosis and the response to immunosuppressive therapy in 64 children with aplastic anemia, using flow fluorescence in situ hybridization. Median age of patients was ten years (range 1.5–16.2 years). Severity of the disease was classified as very severe in 23, severe in 21, and moderate in 20 patients. All patients were enrolled in multicenter studies using antithymocyte globulin and cyclosporine. The response rate to immunosuppressive therapy at six months was 52% (33 of 64). The probability of 5-year failure-free survival and overall survival were 56% (95% confidence interval (CI): 41–69%) and 97% (95%CI: 87–99%), respectively. Median telomere length in responders was −0.4 standard deviation (SD) (−2.7 to +3.0 SD) and −1.5 SD (−4.0 to +1.6 (SD)) in non-responders (P<0.001). Multivariate analysis showed that telomere length shorter than −1.0 SD (hazard ratio (HR): 22.0; 95%CI: 4.19–115; P<0.001), platelet count at diagnosis less than 25×109/L (HR: 13.9; 95%CI: 2.00–96.1; P=0.008), and interval from diagnosis to immunosuppressive therapy longer than 25 days (HR: 4.81; 95%CI: 1.15–20.1; P=0.031) were the significant variables for poor response to immunosuppressive therapy. Conversely to what has been found in adult patients, measurement of the telomere length of lymphocytes at diagnosis is a promising assay in predicting the response to immunosuppressive therapy in children with aplastic anemia. 相似文献
92.
Nao Yoshida Ryoji Kobayashi Hiromasa Yabe Yoshiyuki Kosaka Hiroshi Yagasaki Ken-ichiro Watanabe Kazuko Kudo Akira Morimoto Shouichi Ohga Hideki Muramatsu Yoshiyuki Takahashi Koji Kato Ritsuro Suzuki Akira Ohara Seiji Kojima 《Haematologica》2014,99(12):1784-1791
The current treatment approach for severe aplastic anemia in children is based on studies performed in the 1980s, and updated evidence is required. We retrospectively compared the outcomes of children with acquired severe aplastic anemia who received immunosuppressive therapy within prospective trials conducted by the Japanese Childhood Aplastic Anemia Study Group or who underwent bone marrow transplantation from an HLA-matched family donor registered in the Japanese Society for Hematopoietic Cell Transplantation Registry. Between 1992 and 2009, 599 children (younger than 17 years) with severe aplastic anemia received a bone marrow transplant from an HLA-matched family donor (n=213) or immunosuppressive therapy (n=386) as first-line treatment. While the overall survival did not differ between patients treated with immunosuppressive therapy or bone marrow transplantation [88% (95% confidence interval: 86–90) versus 92% (90–94)], failure-free survival was significantly inferior in patients receiving immunosuppressive therapy than in those undergoing bone marrow transplantation [56% (54–59) versus 87% (85–90); P<0.0001]. There was no significant improvement in outcomes over the two time periods (1992–1999 versus 2000–2009). In multivariate analysis, age <10 years was identified as a favorable factor for overall survival (P=0.007), and choice of first-line immunosuppressive therapy was the only unfavorable factor for failure-free survival (P<0.0001). These support the current algorithm for treatment decisions, which recommends bone marrow transplantation when an HLA-matched family donor is available in pediatric severe aplastic anemia. 相似文献
93.
Hiroshi Moritake Sachiyo Kamimura Hiroyuki Nunoi Hideki Nakayama Aiko Suminoe Hiroko Inada Jiro Inagaki Fumio Yanai Yasuhiro Okamoto Yuichi Shinkoda Maiko Shimomura Nobuyoshi Itonaga Noriko Hotta Yasufumi Hidaka Osamu Ohara Masakatsu Yanagimachi Noriko Nakajima Jun Okamura Yoshifumi Kawano 《International journal of hematology》2014,100(1):70-78
This present study sought to analyze acute lymphoblastic leukemia (ALL) patients with hemophagocytic lymphohistiocytosis (HLH) registered in Kyushu–Yamaguchi Children’s Cancer Study Group studies conducted between 1996 and 2007. Four of 357 patients, including two of 318 patients with B cell precursor acute lymphoblastic leukemia (BCP-ALL) and two of 39 of those with T cell acute lymphoblastic leukemia (T-ALL), were identified. HLH was observed more frequently in the T-ALL patients than in the BCP-ALL patients (P = 0.061). The mean age of 13.0 years at the diagnosis of leukemia in the HLH + ALL group was significantly higher than the 6.05 years observed in the remaining ALL groups (P = 0.001). A female predisposition was noted, as all four patients were female (P = 0.043). In two of four patients, the leukemic cells exhibited deletions on the long arm of chromosome 6 (P = 0.003). Three patients suffered from HLH during maintenance therapy. Parvovirus B19 infection and cytomegalovirus reactivation were identified as causes of HLH in one and two patients, respectively. All four patients are currently in complete remission, although one developed relapse of leukemia after receiving maintenance therapy. Based on the genetic analyses, non-synonymous single nucleotide polymorphisms (SNPs) in UNC13D, syntaxin 11, and STXBP2 were identified in all patients. Clinicians should therefore be aware of the risk of HLH during maintenance therapy, especially in older T-ALL patients with SNPs in familial HLH causative genes. 相似文献
94.
Kousuke Fukazawa Kenji Furuta Kyoichi Adachi Yoshiya Moritou Tsukasa Saito Ryusaku Kusunoki Goichi Uno Shino Shimura Masahito Aimi Shunji Ohara Shunji Ishihara Yoshikazu Kinoshita 《Journal of gastroenterology》2014,49(9):1307-1313
Background
The effects of the prokinetic drug mosapride on esophageal motor activity vary at standard doses. In addition to esophageal motor activities, compliance of the esophagogastric junction (EGJ) is important for prevention of gastroesophageal reflux. However, the effects of mosapride on EGJ compliance have not been reported. Here, we investigated the effects of high-dose mosapride on esophageal motor activities and EGJ compliance.Methods
Nine healthy volunteers were enrolled in the study. Peristaltic esophageal contraction and lower esophageal sphincter pressures before and after administration of 40 mg mosapride were examined by high resolution esophageal manometry. Esophageal compliance was also investigated by intra-esophageal impedance planimetry (EndoFLIP®).Results
High-dose mosapride augmented peristaltic contractions, especially in the distal esophageal segments (P < 0.05). The mean resting lower esophageal sphincter pressure was elevated from 25.0 mmHg before administration to 28.9 mmHg after (P < 0.05). In addition, mosapride significantly reduced EGJ compliance (P < 0.05).Conclusions
Mosapride at 40 mg augmented esophageal motor activities and reduced EGJ compliance in healthy volunteers. 相似文献95.
96.
Ryo Wada MD PhD Masaya Shinohara MD PhD Tadashi Fujino MD PhD Shingo Matsumoto MD PhD Shintaro Yao MD PhD Kensuke Yano MD Shintaro Dobashi MD PhD Katsuya Akitsu MD PhD Hideki Koike MD PhD Hiroshi Ohara MD PhD Toshio Kinoshita MD PhD Hitomi Yuzawa MD PhD Rine Nakanishi MD PhD Takanori Ikeda MD PhD 《Pacing and clinical electrophysiology : PACE》2023,46(1):73-83
97.
Maki Ohara Yumi Funyu Shunsuke Ebara Yuki Sakamoto Ryota Seki Kenta Iijima Akiko Ohishi Junya Kobayashi Kenshi Komatsu Akira Tachibana Hiroshi Tauchi 《Journal of radiation research》2014,55(4):690-698
Ionizing radiation induces DNA double-strand breaks (DSBs). Mammalian cells repair DSBs through multiple pathways, and the repair pathway that is utilized may affect cellular radiation sensitivity. In this study, we examined effects on cellular radiosensitivity resulting from functional alterations in homologous recombination (HR). HR was inhibited by overexpression of the forkhead-associated (FHA) domain-mutated NBS1 (G27D/R28D: FHA-2D) protein in HeLa cells or in hamster cells carrying a human X-chromosome. Cells expressing FHA-2D presented partially (but significantly) HR-deficient phenotypes, which were assayed by the reduction of gene conversion frequencies measured with a reporter assay, a decrease in radiation-induced Mre11 foci formation, and hypersensitivity to camptothecin treatments. Interestingly, ectopic expression of FHA-2D did not increase the frequency of radiation-induced somatic mutations at the HPRT locus, suggesting that a partial reduction of HR efficiency has only a slight effect on genomic stability. The expression of FHA-2D rendered the exponentially growing cell population slightly (but significantly) more sensitive to ionizing radiation. This radiosensitization effect due to the expression of FHA-2D was enhanced when the cells were irradiated with split doses delivered at 24-h intervals. Furthermore, enhancement of radiation sensitivity by split dose irradiation was not seen in contact-inhibited G0/G1 populations, even though the cells expressed FHA-2D. These results suggest that the FHA domain of NBS1 might be an effective molecular target that can be used to induce radiosensitization using low molecular weight chemicals, and that partial inhibition of HR might improve the effectiveness of cancer radiotherapy. 相似文献
98.
Michinori Funato Osamu Uemura Katsumi Ushijima Hidenori Ohnishi Kenji Orii Zenichiro Kato Satoshi Yamakawa Takuhito Nagai Osamu Ohara Hideo Kaneko Naomi Kondo 《Journal of clinical immunology》2014,34(6):691-695
Purpose
Gain-of-function mutations in complement factor B (CFB) were recently identified in patients with atypical hemolytic uremic syndrome (aHUS), but are extremely rare. Our purpose is to describe a large kindred with aHUS associated with a CFB mutation and to further understand CFB-mutated aHUS patients.Methods and Results
We report a large kindred in which 3 members had aHUS. This kindred revealed that 9 of 12 members, including 2 affected patients, had persistent activation of the alternative pathway with low complement component 3 and that those 9 members showed a CFB mutation (c.1050G?>?C, p.Lys350Asn) in exon 8. This missense mutation was heterozygous in 8 of them and homozygous in only one. From structural studies, this mutation is shown to be located in close proximity to the Mg2-binding site within a von Willebrand factor type A domain of CFB, resulting in a gain-of-function effect of CFB and predisposition to aHUS. At present, 2 of the 3 members with aHUS have maintained normal renal function for a long-term period.Conclusions
This kindred illustrates that a CFB mutation (c.1050G?>?C, p.Lys350Asn) can result in aHUS. In the future, phenotype-genotype correlations and outcome in CFB-mutated aHUS patients need to be further investigated by accumulation of a number of cases. 相似文献99.
Amit Rawat Surjit Singh Deepti Suri Anju Gupta Biman Saikia Ranjana Walker Minz Shobha Sehgal Kim Vaiphei C. Kamae K. Honma N. Nakagawa K. Imai S. Nonoyama K. Oshima N. Mitsuiki O. Ohara Koon-Wing Chan Yu Lung Lau 《Journal of clinical immunology》2014,34(1):58-67
Chronic granulomatous disease (CGD) results from an inherited defect in the phagocytic cells of the immune system. It is a genetically heterogenous disease caused by defects in one of the five major subunits of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex. There is a paucity of data from India on CGD. We herein describe the clinical features in 17 children with CGD from a single tertiary referral center in India. A detailed analysis of the clinical features, laboratory investigations and outcome of 17 children 7 with X-linked (XL) and 10 with autosomal recessive (AR) form was performed. Diagnosis of CGD was based on an abnormal granulocyte oxidative burst evaluated by either Nitroblue Tetrazolium (NBT) test or flow cytometry based Dihyrorhodamine 123 assay or both. The molecular diagnosis was confirmed by genetic mutation analysis in 13 cases. The mean age at diagnosis and the age at onset of symptoms was significantly lower in children diagnosed with XL- CGD compared those with AR disease. Mutations were detected in CYBB gene in 6 patients with XL-CGD and NCF-1 gene mutations were observed in 7 cases of AR- CGD. The course and outcome of the disease was much worse in children diagnosed with X-linked form of disease compared to AR forms of the disease; 4/7 (57 %) children with X-CGD were dead at the time of data analysis. This is one of the largest series on chronic granulomatous disease from any developing country. 相似文献